Literature DB >> 3243739

Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin.

J Kavi1, J M Andrews, J P Ashby, G Hillman, R Wise.   

Abstract

The pharmacokinetics and tissue penetration (as measured by a blister fluid model) of cefpirome were studied in six male volunteers following a 1 g intravenous dose. A mean peak serum concentration (at 5 min) of 97.4 mg/l was followed by rapid distribution into an apparent volume of 21.3 1. The serum elimination half-life was 2.3 h. Cefpirome penetrated rapidly into inflammatory fluid with a mean peak concentration of 39.2 mg/l at 1.9 h. The mean inflammatory fluid elimination half-life was 2.5 h. The availability of the drug in inflammatory fluid was high with a mean per cent penetration of 123%. The plasma and renal clearances were 109.5 and 82.1 ml/min respectively. Twenty-four hour urinary recovery was 75.5% of the administered dose. This study suggests that a twice daily dosage may be sufficient to treat tissue infections with susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243739     DOI: 10.1093/jac/22.6.911

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.

Authors:  P O'Neill; K Nye; G Douce; J Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

2.  Intraperitoneal penetration of cefpirome.

Authors:  J Kavi; J P Ashby; R Wise; I A Donovan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

Review 3.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  Pharmacokinetics and distribution in tissue of FK-037, a new parenteral cephalosporin.

Authors:  R Wise; J M Andrews; P O'Neill; A Jolley; C Fowler; M C Rogge
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.

Authors:  Robert Sauermann; Georg Delle-Karth; Claudia Marsik; Ilka Steiner; Markus Zeitlinger; Bernhard X Mayer-Helm; Apostolos Georgopoulos; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; M Kinzig; C B Landersdorfer; U Holzgrabe; U Stephan; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 8.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 9.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.

Authors:  D Paradis; F Vallée; S Allard; C Bisson; N Daviau; C Drapeau; F Auger; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.